The Journal of Targeted Therapies in Cancer

Cervical cancer screening based on identification of human papillomavirus (HPV) outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN).
Dacomitinib has demonstrated potential as treatment for a subset of patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
The bromodomain inhibitor, OTX015, may have use in the treatment of hematologic malignancies, including acute leukemia and other hematologic malignancies that include lymphomas and multiple myeloma.
Allogeneic hematopoietic cell transplant (alloHCT) can be a mysterious process for patients and general oncologists.
For nearly 2 decades, researchers have been exploring B-cell–specific antigens in hopes of developing a new anticancer target that could surpass the success of CD20-targeting agents.
The concept of cancer immunotherapy— using the patient’s immune system to target and eradicate cancer—has evolved over more than a century of research.
The combination of surgery, radioactive iodine (RAI), and L-thyroxine therapy is effective treatment for patients with differentiated thyroid cancer (DTC), which accounts for some 95% of all thyroid cancers.
JTT Articles
Dacomitinib Shows Responses in Subset of Head and Neck Cancer
MEK Inhibitors
Graft Versus Host Disease for the General Oncologist
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.